Randomized, double-blind study of SR142801 (Osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challenges. - Kronenberg,G.; Berger,P.; Tauber,RF.; Bandelow,B.; Henkel,V.; Heuser,I. (Pharmacopsychiatry, 2005)